Understanding how specific immune receptors affect brain cancer growth
Official title: Deciphering TREM1/2 Function in Primary Brain Cancer Using a New Model of Glioblastoma
Funded at Beth Israel Deaconess Medical Center · NIH-10999313 · Data updated 2026-11-12
This study is looking at how two immune receptors, Trem1 and Trem2, affect the body's immune response to glioblastoma, a tough type of brain cancer, and it aims to find new ways to help patients by understanding how these receptors influence tumor growth and treatment resistance.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Beth Israel Deaconess Medical Center NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | August 1, 2024 |
| Project end | July 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $472,124 |
| NIH project number | 1R21NS139480-01 |
| Project ID | NIH-10999313 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with glioblastoma who may benefit from novel immunotherapeutic approaches.
✕Less likely to help
Patients with other types of brain tumors or those who are not diagnosed with glioblastoma may not receive any benefit from this research.
What this research studies
This research investigates the roles of two immune receptors, Trem1 and Trem2, in the context of glioblastoma, a highly aggressive brain cancer. Using a novel mouse model, the study aims to explore how these receptors influence the immune response in the bone marrow when glioblastoma is present. By selectively eliminating these receptors in specific immune cells, researchers will analyze changes in the tumor microenvironment and how this might affect tumor growth and resistance to treatment. The findings could provide insights into new therapeutic strategies for glioblastoma patients.
Why it matters
Potential benefit: If successful, this research could lead to new treatment options that enhance the immune response against glioblastoma.
How similar studies have gone: Previous research has shown promising results in targeting immune receptors in cancer treatment, suggesting potential for success in this approach.
Where this research is happening
-
Beth Israel Deaconess Medical Center
Boston, United States Active
Researchers
- Principal investigator: Charest, Alain — Beth Israel Deaconess Medical Center
- Study coordinator: Charest, Alain
Related research
Other NIH-funded projects on the same topics.
-
Small molecules to block Slit2/ROBO in glioblastoma
A study to test small molecule drugs that block Slit2/ROBO signals to help treat glioblastoma in patients.
-
Immunotherapy for glioblastoma: advancing treatment and understanding
A patient-friendly summary of a grant exploring new immune-based treatments for glioblastoma to improve options for people affected by this brain cancer.
-
Small-molecule and biologic treatments for glioblastoma using targeted brain delivery
A new approach aims to use FPS-ZM1 to shrink brain swelling and support immunotherapy for glioblastoma, potentially helping patients recover after surgery.
-
Targeted therapies for glioblastoma in adults and kids
A large NIH program is exploring new brain cancer therapies, including drugs that reach the brain and work against glioblastoma in both children and adults.
-
6-thio-2'-deoxyguanosine for glioblastoma: a new approach to target tumors before surgery
A trial tests a novel drug given before glioblastoma surgery to see how it behaves in the body and within the tumor, and to learn how it affects cancer cells and the immune environment.
-
CD38-Driven Changes in Brain Tumor Metabolism and Immunity in Glioblastoma
A patient-facing look at how scientists plan to study how glioblastoma grows by changing its metabolism and dampening the immune response, with potential targets to help treatment in the future.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.